|
A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613. |
|
Kanwal Pratap Singh Raghav |
Consulting or Advisory Role - Bayer (Inst); Genentech (Inst) |
Travel, Accommodations, Expenses - TRACON Pharma |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Roche/Genentech |
Research Funding - Bayer; Boehringer Ingelheim; Eisai; Exelixis; Lilly; Merck Serono; Pfizer; Roche/Genentech; Sillajen; tyrogenex |
|
|
Consulting or Advisory Role - Carevive Systems; EMD Serono; Lilly; Merck; Merrimack |
Research Funding - Advaxis (Inst); Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merrimack (Inst); OncoMed (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech/Roche |
|
|
Employment - QTC Management- A Leidos Company |
Travel, Accommodations, Expenses - QTC Management- A Leidos Company |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - MolecularMatch; Navire |
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution |
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst) |
|
|
Honoraria - Sirtex Medical |
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche |
Speakers' Bureau - Amgen; Taiho Pharmaceutical |
Research Funding - Merck (Inst); Novartis (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical |